Two-stage interaction of the tumor nursing galectin-1 with the antiangiogenic peptide anginex

被引:0
作者
Zsófia Hegedüs
Edit Wéber
Lea Végh
Balázs Váczi
Vilmos Tubak
Éva Kriston-Pál
Zoltán Kele
Éva Monostori
Tamás A. Martinek
机构
[1] University of Szeged,SZTE
[2] Biological Research Center of the Hungarian Academy of Sciences,MTA Lendulet Foldamer Research Group, Institute of Pharmaceutical Chemistry
[3] University of Szeged,Lymphocyte Signal Transduction Laboratory, Institute of Genetics
[4] University of Szeged,Department of Medical Chemistry
来源
Journal of Thermal Analysis and Calorimetry | 2015年 / 120卷
关键词
Isothermal titration calorimetry; Anginex; Galectin-1; Angiogenesis;
D O I
暂无
中图分类号
学科分类号
摘要
The 33mer peptide anginex is a potent inhibitor of angiogenesis and tumor growth. Its biological activity is dependent on the β-galactoside-binding protein galectin-1 (gal-1), which has been reported to be the main receptor for anginex. The gal-1–anginex interaction has been observed using surface plasmon resonance and mass spectrometric methods, but the stoichiometry and affinity in the solution remain elusive. Our aim was to characterize the gal-1–anginex interaction via isothermal titration calorimetry. In order to ensure protein purity and integrity, native gel electrophoresis, Western blot analysis, mass spectrometric measurements, and ultracentrifugation were carried out for the recombinant wild-type human gal-1 and V5D gal-1 expressed in E. coli. Two stages were identified in the titration curves: (i) formation of a 4:1 galectin-1–anginex complex with low nM affinity, and (ii) a complex with 1:1 stoichiometry exhibiting KD > 200 nM. The 4:1 complex was robust at different concentrations, and neither the oxidation state nor the V5D mutation (a monomeric gal-1 mutant) of gal-1 affected this stoichiometry. The presence of the high-affinity 4:1 interaction may have implications for the biological applications of anginex.
引用
收藏
页码:449 / 456
页数:7
相关论文
共 152 条
[11]  
Griffioen AW(2003)Beta-sheet is the bioactive conformation of the anti-angiogenic anginex peptide Biochem J 373 281-288
[12]  
Griffioen AW(2007)Galectins in the tumor endothelium: opportunities for combined cancer therapy Blood 110 2819-2827
[13]  
van der Schaft DW(2006)Galectin-1: a small protein with major functions Glycobiology 16 137R-157R
[14]  
Barendsz-Janson AF(2007)Galectins—potential targets for cancer therapy Cancer Lett 253 25-33
[15]  
Cox A(2008)Galectin-1 as a potential therapeutic target in autoimmune disorders and cancer Expert Opin Biol Ther 8 45-57
[16]  
Struijker Boudier HA(2004)Growth-regulatory human galectin-1: crystallographic characterisation of the structural changes induced by single-site mutations and their impact on the thermodynamics of ligand binding J Mol Biol 343 957-970
[17]  
Hillen HF(2010)Monovalent interactions of galectin-1 Biochemistry 49 9518-9532
[18]  
van der Schaft DW(1995)Galectin-1, a beta-galactoside-binding lectin in Chinese hamster ovary cells. I. Physical and chemical characterization J Biol Chem 270 5198-5206
[19]  
Dings RP(2012)Advances and prospects of anginex as a promising anti-angiogenesis and anti-tumor agent Peptides 103 15975-15980
[20]  
de Lussanet QG(2006)Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy Proc Natl Acad Sci USA 286 13801-13804